Ganga Pharmaceuticals Ltd Stock Price Today (NSE: GANGAPHARM)
Fundamental Score
Ganga Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Ganga Pharmaceuticals Ltd share price today is ₹12.00, up +0.00% on NSE/BSE as of 3 August 2026. Ganga Pharmaceuticals Ltd (GANGAPHARM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹6.90 (Cr). The 52-week high for GANGAPHARM share price is ₹14.60 and the 52-week low is ₹9.35. At a P/E ratio of 86.25x, GANGAPHARM is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 1.13% and a debt-to-equity ratio of 0.19.
Ganga Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Ganga Pharmaceuticals Ltd share price chart: 0.00% return over the past month. 52-week high ₹14.60, 52-week low ₹9.35.
Ganga Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹12.00 | ₹12.00 | ₹12.00 | ₹12.00 | 0.00 (Cr) | |
| ₹12.00 | ₹12.00 | ₹12.00 | ₹12.00 | 0.00 (Cr) | |
| ₹12.00 | ₹12.00 | ₹12.00 | ₹12.00 | 0.00 (Cr) | |
| ₹12.00 | ₹12.00 | ₹12.00 | ₹12.00 | 0.00 (Cr) | |
| ₹12.00 | ₹12.00 | ₹12.00 | ₹12.00 | 0.00 (Cr) | |
| ₹12.00 | ₹12.00 | ₹12.00 | ₹12.00 | 0.00 (Cr) | |
| ₹12.00 | ₹12.00 | ₹12.00 | ₹12.00 | 0.00 (Cr) | |
| ₹12.00 | ₹12.00 | ₹12.00 | ₹12.00 | 0.00 (Cr) | |
| ₹12.00 | ₹12.00 | ₹12.00 | ₹12.00 | 0.00 (Cr) | |
| ₹12.00 | ₹12.00 | ₹12.00 | ₹12.00 | 0.00 (Cr) |
Ganga Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹12.00 | ₹12.00 | ₹12.00 | ₹12.00 | +0.00% | |
| ₹12.00 | ₹12.00 | ₹12.00 | ₹12.00 | +0.00% | |
| ₹12.00 | ₹12.00 | ₹12.00 | ₹12.00 | +0.00% | |
| ₹12.00 | ₹12.00 | ₹12.00 | ₹12.00 | +0.00% | |
| ₹12.00 | ₹12.00 | ₹12.00 | ₹12.00 | +0.00% | |
| ₹12.00 | ₹12.00 | ₹12.00 | ₹12.00 | +0.00% | |
| ₹11.68 | ₹13.97 | ₹9.35 | ₹12.00 | +2.74% | |
| ₹11.68 | ₹11.68 | ₹11.68 | ₹11.68 | +0.00% | |
| ₹14.60 | ₹14.60 | ₹11.68 | ₹11.68 | -20.00% | |
| ₹14.60 | ₹14.60 | ₹14.60 | ₹14.60 | +0.00% | |
| ₹14.60 | ₹14.60 | ₹14.60 | ₹14.60 | +0.00% | |
| ₹14.60 | ₹14.60 | ₹14.60 | ₹14.60 | +0.00% |
AI Research Briefing
Powered by Gemini · 2026-08-01
A fundamentally broken micro-cap trap trading at an unjustifiable valuation with zero institutional support.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. Routine regulatory compliance filings and certificate updates under SEBI regulations were submitted in early July 2026, but zero institutional order wins, corporate expansions, or earnings surprises have materialized.
CORE STORY (THE REAL GAME)
An illiquid micro-cap shell trading on nostalgic ayurvedic branding with zero institutional sponsorship and negative free cash flow generation.
- P/E ratio at 86.25x massively outpaces the 31.77x industry average
- 5-year cumulative free cash flow sits deeply negative at -2.43 crore
- Zero institutional or foreign interest with FII and DII holdings at 0.0%
- Sudden speculative retail momentum in micro-cap ayurvedic stocks
- Aggressive promoter equity infusion or asset restructuring
- Unlikely large-scale institutional bulk deals
- Extreme micro-cap liquidity risk leading to total execution lockup
- Dismal return metrics with an ROCE of 3.18% and ROE of 1.13%
- Stagnant top-line performance with negative multi-year profit growth
Promoters hold 50.91% with zero delta change, while FII and DII participation remains completely absent at 0.0%.
Broader Indian pharma sector is scaling towards complex generics and massive policy tailwinds, leaving stagnant micro-caps behind.
No major news found after live search.
no, use ₹ figure
Continued range-bound stagnation and volume starvation due to complete lack of operational triggers.
Primary Thesis Risk
Complete absence of liquidity combined with value destruction will trap capital indefinitely.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Ganga Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Ganga Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GANGAPHARM across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Conservative Debt Levels (D/E: 0.19)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (50.91%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
10 factors identified
Below-Average Return on Equity (1.13%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (3.18%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (0.00%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Premium Valuation Risk (P/E: 86.25x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Growth History (-3.67% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-18.77% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-15.89% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (1.38x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-2.43 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Ganga Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Ganga Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Ganga Pharmaceuticals LtdGanga Pharmaceu...Selected✓ GANGAPHARM • 539680 | 13/100 | ₹12.00₹12 | ₹6.90₹6.90 | 86.25Average 86.3 Average | 1.13%Poor 1.13% Poor | 3.18%Poor 3.18% Poor | 0.19Excellent 0.2 Excellent | -15.89%Poor -15.89% Poor | -3.67%Poor -3.67% Poor | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Ganga Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for GANGAPHARM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
4.58%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
0.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-3.67%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-15.89%
Compounded annual net profit growth over 5 years
Ganga Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for GANGAPHARM — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Ganga Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Ganga Pharmaceuticals Ltd (GANGAPHARM) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Ganga Pharmaceuticals Ltd
About GANGAPHARM (Ganga Pharmaceuticals Ltd)
Ganga Pharmaceuticals Ltd. is a pioneering force in the realm of natural healthcare, dedicated to harnessing the ancient wisdom of Ayurveda to create innovative and effective pharm...aceutical solutions. With a legacy spanning several decades, the company is deeply rooted in the rich traditions of Indian medicine, while simultaneously embracing cutting-edge scientific advancements. Gangapharm is committed to delivering high-quality ayurvedic formulations that address a wide spectrum of health concerns, from chronic ailments to preventative care. Our emphasis is on using sustainably sourced, potent herbal ingredients and rigorous quality control measures to ensure product efficacy and safety. We strive to empower individuals to take charge of their well-being through natural and holistic approaches. At the heart of Gangapharm's philosophy lies a profound respect for the environment and a deep commitment to ethical business practices. We work closely with local communities and farmers to promote sustainable cultivation and harvesting of medicinal plants, ensuring the long-term availability of raw materials. Our state-of-the-art manufacturing facilities adhere to the highest global standards, guaranteeing the purity and potency of every product. Ganga Pharmaceuticals fosters a culture of innovation, constantly exploring new formulations and delivery methods to enhance the therapeutic benefits of Ayurveda. We are dedicated to providing healthcare practitioners and consumers with reliable, evidence-based solutions that promote optimal health and vitality. Ganga Pharmaceuticals is more than just a pharmaceutical company; it is a custodian of ancient knowledge and a champion of natural healing. Through our unwavering commitment to quality, sustainability, and innovation, we aim to be a trusted partner in the journey towards holistic well-being. We envision a future where Ayurveda plays an integral role in mainstream healthcare, offering safe, effective, and natural alternatives to conventional treatments. Ganga Pharmaceuticals is dedicated to making this vision a reality, one innovative formulation at a time, and one healthy individual at a time. We are dedicated to improving lives through the healing power of nature.
Company Details
Key Leadership
GANGAPHARM Share Price: Frequently Asked Questions
What is the current share price of Ganga Pharmaceuticals Ltd?
Ganga Pharmaceuticals Ltd (GANGAPHARM) trades at ₹12.00 on NSE and BSE. Market cap ₹6.90 (Cr). Educational data only.
What is the P/E ratio of Ganga Pharmaceuticals Ltd?
Ganga Pharmaceuticals Ltd has a P/E of 86.25x vs industry average 31.77x.
What is the Bull Run score for Ganga Pharmaceuticals Ltd?
Ganga Pharmaceuticals Ltd has a Bull Run score of 13/100 based on 25+ financial parameters.
Does Ganga Pharmaceuticals Ltd pay dividends?
Ganga Pharmaceuticals Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Ganga Pharmaceuticals Ltd?
Ganga Pharmaceuticals Ltd has ROE of 1.13%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Ganga Pharmaceuticals Ltd?
Ganga Pharmaceuticals Ltd has debt-to-equity of 0.19.
Is Ganga Pharmaceuticals Ltd a good investment?
Bull Run gives Ganga Pharmaceuticals Ltd a score of 13/100. This is not investment advice — consult a SEBI-registered advisor.